Advances in Clinical Medicine
Vol. 13  No. 06 ( 2023 ), Article ID: 67263 , 6 pages
10.12677/ACM.2023.1361341

性激素结合球蛋白在多囊卵巢综合征的研究 进展

常小莹*,郭守萍

黑龙江中医药大学研究生院,黑龙江 哈尔滨

收稿日期:2023年5月16日;录用日期:2023年6月9日;发布日期:2023年6月19日

摘要

多囊卵巢综合征(PCOS)是引起育龄妇女不孕症的常见生殖内分泌疾病。临床上以高雄激素血症(HA)、慢性无排卵和多囊卵巢形态(PCOM),胰岛素抵抗常见。性激素结合球蛋白(SHBG)是一种结合雌激素和雄激素并调节其生物活性的转运载体,一般用作PCOS女性雄激素过多症的指标。当血清SHBG水平降低时认为是代谢异常,且与PCOS患者的胰岛素抵抗(IR)、HA以及葡萄糖和脂质代谢异常有关。近几年来研究发现,中药可以降低SHBG水平,恢复卵巢形态,缓解PCOS临床症状。

关键词

PCOS,性激素结合球蛋白,高雄激素血症,糖脂代谢异常,中药

Advances of the Regulation of Sex-Hormone Globulin in Polycystic Ovary Syndrome

Xiaoying Chang*, Shouping Guo

Graduate School of Heilongjiang University of Chinese Medicine, Harbin Heilongjiang

Received: May 16th, 2023; accepted: Jun. 9th, 2023; published: Jun. 19th, 2023

ABSTRACT

Polycystic ovary syndrome (PCOS) is a common reproductive endocrine disease that causes infertility in women of childbearing age. Clinically, insulin resistance is common with hyperandrogenemia (HA), chronic anovulation and polycystic ovary morphology (PCOM). Sex hormone binding globulin (SHBG), a transporter that binds estrogen and androgen and regulates their biological activity, is commonly used as an indicator of female androgen hyperplasia in PCOS. When serum SHBG water is reduced, it is considered to be metabolic abnormality, which is associated with insulin resistance (IR), HA, glucose and lipid metabolism abnormalities in PCOS patients. In recent years, it has been found that traditional Chinese medicine can reduce SHBG level, restore ovary shape and relieve PCOS clinical symptoms.

Keywords:PCOS, SHBG, HA, Glucose/Metabolic Disease, Traditional Chinese Medicine

Copyright © 2023 by author(s) and Hans Publishers Inc.

This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).

http://creativecommons.org/licenses/by/4.0/

1. 引言

多囊卵巢综合征(polycystic ovary syndrome, PCOS)是育龄期妇女常见的内分泌、心理、免疫相关的生殖与代谢异常性疾病,发病率为5%~20%,已严重影响女性的生理和心理健康 [1] ,其临床表现为月经不调、闭经、肥胖、多毛、痤疮等,并且远期患2型糖尿病(T2DM),子宫内膜癌,不孕症,情绪和饮食失调,心血管疾病,代谢综合征的风险更大。PCOS病因不明,病理机制复杂,可能主要与下丘脑–垂体–卵巢轴和肾上腺功能不全、遗传、代谢和环境等因素有关,高雄激素血症(HA)被认为是PCOS的关键特征,PCOS患者中性激素结合球蛋白SHBG的浓度通常较低,SHBG是一种性激素转运蛋白,由肝脏产生,与循环性类固醇结合,具有高亲和力,调节血液中生物活性性激素的浓度,影响其生物利用度 [2] 。因此,SHBG可用于评估高雄激素血症的严重程度和评估治疗效果。PCOS的并发症及远期预后可能与血清SHBG有关,血清SHBG在PCOS的发病机制中起非常重要的作用。

2. SHBG的概述

SHBG是一种90~100 kDa同源二聚体糖蛋白,具有两条相同的肽链,SHBG基因位于染色体17p13.1上,表达受刺激的肝细胞核因子4α (HNF-4α)、组成性雄甾烷受体和抑制性过氧化物酶体 [3] 。HNF-4α是最重要的转录因子,受到甲状腺激素,脂联素以及各种细胞因子,例如肿瘤坏死因子-α (TNF-α)等的影响 [4] ,通过与位于SHBG启动子上游的DR1和DR3顺式元件结合位点结合来激活肝脏中的SHBG表达 [5] ,SHBG浓度会影响血浆中游离活性T的浓度的影响,因为65%的T与SHBG结合,其余的与白蛋白结合,所以循环中只有1%~2%的T是游离和活跃的 [6] 。因此,SHBG可用于评估HA严重程度以及PCOS的治疗效果。

3. SHBG水平对于PCOS患者的影响

3.1. SHBG水平和高雄激素血症

PCOS患者中大概有70%~80%出现高雄激素血症,主要临床表现为痤疮,多毛,溢脂以及脱发。在PCOS患者中,过量的雄激素主要由卵巢和肾上腺产生,会影响优势卵泡的形成,导致滤泡闭锁,最终导致排卵障碍。有研究表明在PCOS患者中,尤其是肥胖的青春期女性,血清SHBG水平是降低的 [7] 。SHBG通过结合游离雄激素来降低HA和IR,从而降低游离睾酮(FT)水平。与健康个体相比,PCOS患者的雄激素(T)水平明显更高,SHBG水平与T水平呈负相关,与T对SHBG的影响不同,E2增加了肝脏中SHBG的水平,可能是由于雌激素受体α (ER-α)介导的HNF-4α基因表达的上调 [8] 。研究表明,HepG2细胞中的T抑制SHBG的产生 [9] ,即使在低剂量下,外源性雄激素也可以抑制SHBG [10] 。

3.2. SHBG水平和胰岛素抵抗

PCOS患者中胰岛素抵抗(IR)占50%~70% [11] ,IR是指靶细胞对正常胰岛素水平反应降低,使胰岛素对葡萄糖的利用、摄取能力下降,血糖升高,而机体代偿性胰岛素分泌过多 [12] 。因IR产生的高胰岛素血症被认为是PCOS代谢紊乱与生殖功能障碍之间关系的重要原因。高胰岛素血症会阻止SHBG的分泌和合成,研究发现高胰岛素血症患者的血清SHBG水平明显降低 [13] ,且研究发现,具有IR和低SHBG水平的PCOS患者是不孕症的高风险人群 [14] 。胰岛素被认为是SHBG代谢的重要调节剂,当胰岛素敏感性降低,胰岛素代偿性分泌增加时,下调SHBG基因转录和SHBG产生 [15] 。有动物研究表明,过表达SHBG能够抑制高脂肪饮食(HFD)大鼠出现肥胖和胰岛素抵抗 [16] ,当甘油三酯在肝脏中蓄积,IR与SHBG mRNA、HNF-4 α mRNA和循环SHBG水平呈负相关。另外高胰岛素血症下调HNF-4α表达进而上调乙酰辅酶A羧化酶(ACC)脂肪生成来减少肝脏中SHBG的产生 [17] 。尽管SHBG影响IR的机制尚不完全清楚,但体外研究表明,SHBG蛋白可能通过PI3K/AKT途径降低IRS-1,IRS-2,PI3Kp85a,GLUT-3和GLUT-4的表达,从而导致局部和全身IR的发展 [18] 。

3.3. SHBG水平和卵巢功能

在青春期PCOS的患者中,SHBG水平过低与脂肪肝和高胰岛素血症有关,研究发现,PCOS伴有非酒精性脂肪性肝病(NAFLD)患者的,肝脏中SHBG合成的减少使得血液中游离雄激素的持续增加,进一步导致卵巢雄激素分泌过多,从而降低下丘脑对促黄体生成素(LH)脉冲的敏感性,进而刺激垂体释放LH [19] [20] ,又导致卵巢分泌过度的雄激素,由此形成恶性循环,导致PCOS的发展。由此可以推测,肝脏脂肪生成增加可能会抑制肝脏SHBG合成,导致PCOS患者的相对和绝对HA和卵巢功能障碍。相反,当给予低碳水化合物饮食会减少肝脏脂肪产生,从而增加SHBG的产生,恢复生殖功能 [21] [22] 。

3.4. SHBG水平与脂代谢异常

脂肪组织是一种非常重要的内分泌组织,可分泌多瘦素、脂联素、抵抗素、内脏脂蛋白等多种活性脂肪因子和TNF-α、C反应蛋白(CRP)、白细胞介素-1 (IL-1)和白细胞介素-6 (IL-6)等炎症因子,导致局部炎症发生并且加重IR [23] 。研究发现,炎性细胞因子可能调节SHBG表达,PCOS患者随着CRP、TNF-α、IL-1和IL-6的循环水平升高,血清SHBG水平降低,肝脏脂肪生成增加导致脂联素水平降低,进一步下调HNF-4α的水平,导致SHBG水平降低 [24] [25] 。另外,从肝脏脂肪释放的TNF-α会损害肝脏胰岛素信号传导并促进甘油三酯在肝脏中的积累,导致通过NF-κB抑制HNF-4αmRNA [26] [27] 。相反,体外研究表明,高水平SHBG能够抑制巨噬细胞和脂肪细胞中的炎症和脂质积累,从而降低并发症代谢综合征发生率 [28] 。

4. 中医对于性激素结合球蛋白的调控

4.1. 当归芍药散加味联合达英-35

当归芍药散出自《金匮要略》,当归、白芍、川芎、茯苓、泽泻、白术,六味药肝脾同调,当归芍药散加味加之山茱萸、枸杞子、熟地黄、巴戟天、附子,全方具有补肾益精、活血行气之效。张杰等 [29] 研究发现,相比于西药组,联合组中医证候积分,ACTH水平更低,而血清SHBG水平更高,临床疗效更好,而不良反应更少,探究其具体机制,发现两组PI3K、Akt、p-Akt蛋白相对表达量均升高,但联合组较西药组更高,从而激活PI3K/AKT信号通路,另外也会影响下丘脑递质分泌的从而调节下丘脑–垂体–卵巢–子宫轴,纠正PCOS患者性激素紊乱,缓解其临床症状。

4.2. 补肾调经育子汤联合来曲唑

补肾调经育子汤中紫石英、菟丝子、女贞子、熟地黄、杜仲、牛膝诸药联用,全方具有祛痰除瘀、标本兼治、阴阳互补等作 [30] 。闫嘉营 [31] 等研究发现,相比于仅使用来曲唑组,补肾调经育子汤联合来曲唑组其血清SHBG水平更高,visfatin水平更低,visfatin可促进炎性因子表达,能和胰岛素受体相互作用,出现类似于胰岛素抵抗作用,加速PCOS进展,治疗后两组血清LH、T、LH/FSH水平均降低,且补肾调经育子汤联合来曲唑组较来曲唑组更低,并且其卵泡直径、成熟卵泡个数及优势卵泡数高于都优于来曲唑组,说明补肾调经育子汤联合来曲唑可以改善PCOS患者性激素水平,恢复卵巢功能且较单独使用来曲唑更好。

4.3. 穴位埋线

何丹娟 [32] 等选取1) 肝俞、中极、膈俞、足三里、三阴交、带脉、关元;2) 肾俞、脾俞、天枢、水分、阴陵泉、丰隆、卵巢;每次一组,两组交替进行。临床研究结果表明,穴位埋线组相比于西药组其更能改善肥胖型PCOS患者体重、腰围、BMI、WHR,其临床疗效更好,另外升高SHBG水平更明显,不良反应发生率更低。其具体机制:埋置于体内穴位针能够持续不断的刺激局部组织和经络系统,从而调控多种途径的中枢通路以及外周通路,通过减轻体重、提高SHBG水平、使雄激素水平降低、并且调节下丘脑-垂体-卵巢轴的功能,最终缓解PCOS临床症状。

4.4. 加味补肾活血调经汤联合桂枝茯苓胶囊

加味补肾活血调经汤方中有紫石英、仙灵脾续断、菟丝子、当归、鸡血藤、香附、枸杞子、白芍、熟地黄、莪术、川椒、炙甘草,全方具有活血化瘀、补肾理气调经之功,桂枝茯苓胶囊是妇科经典名方,具有活血化瘀、消癥散结功效,两方合用,攻补兼施,疗效更佳。王铭 [33] 等研究发现,采取加味补肾活血调经汤联合桂枝茯苓胶囊组比起单独使用西药血清SHBG水平更高,Visfatin水平更低,另外,其治疗总有效率与预后排卵率、妊娠率高于西药组,流产率及血清 LH、T、LH/FSH水平低于西药组,证明了加味补肾活血调经汤联合桂枝茯苓胶囊治疗可明显提高治疗效果,改善机体性激素水平,恢复卵巢功能。

4.5. 益肾祛浊方

益肾祛浊方是由续断、桑寄生、败酱草等12味中药组成,研究 [34] 发现此方能使低水平Ghrelin升高,Ghrelin是一种活性多肽,其具有强促生长激素释放功能,能调控中枢、卵巢及胃肠道多种反应 [35] ,另外提高SHBG水平,降低雄激素水平,同时能使异常升高的FINS与VF水平降低,VF可以调节糖脂代谢,主要是通过调控脂肪细胞分化和存储以及类胰岛素样作用 [36] 。由此证明益肾祛浊方通过提高Ghrelin和SHBG水平,降低VF水平,通过改善内分泌紊乱以及体内慢性炎症状态,遏制PCOS-IR的恶性循环,恢复生殖轴功能,缓解PCOS多种临床症状。

4.6. 滋阴补阳方序贯法联合西药

其方法是月经周期第5天起给予达英-35,每次1片,每天1次,口服,共21天,共治疗3个月经周期,此为对照组,观察组是在此基础上在卵泡期服用滋阴方,组方:干地黄、山茱萸、菟丝子、紫河车、当归、白芍各10 g,每天1剂,水煎服,每天2次。经前期服用补阳方,组方:巴戟天、续断、补骨脂、淫羊藿、党参、淮山药各10 g,共治疗3个月经周期。孙玉英 [37] 等通过实验证明,滋阴补阳方序贯法联合西药提高PCOS患者黄体中期子宫内膜HOXA10 mRNA的表达,提高子宫内膜容受性,降低PCOS患者高雄激素血症血清LH、T、DHEAS水平,升高SHBG水平,缓解临床症状,疗效优于仅仅使用西药。

5. 小结

PCOS因其病因具有多样性,临床特征具有异质性,是一种复杂的生殖内分泌代谢性疾病,而SHBG由肝脏产生,能够调控循环中性激素有效的生物浓度,且还能够影响胰岛素抵抗、糖脂代谢及炎症水平,最终影响卵巢的生殖功能,可以为PCOS的早期诊断及预后评估提供重要参考。近些年来,中医药在调控SHBG方面发挥了显著作用,但其具体机制,以及所涉及到的信号通路仍有待我们进一步去探索研究,为PCOS的药物治疗提供新的方法和思路。

文章引用

常小莹,郭守萍. 性激素结合球蛋白在多囊卵巢综合征的研究进展
Advances of the Regulation of Sex-Hormone Globulin in Polycystic Ovary Syndrome[J]. 临床医学进展, 2023, 13(06): 9586-9591. https://doi.org/10.12677/ACM.2023.1361341

参考文献

  1. 1. Teede, H.J., Misso, M.L., Costello, M.F., et al. (2019) Erratum. Recommendations from the International Evidence- Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Human Reproduction, 34, 388. https://doi.org/10.1093/humrep/dey363

  2. 2. Hammond, G.L.,Wu, T.-S. and Simard, M. (2012) Evolving Utility of Sex Hormone-Binding Globulin Measurements in Clinical Medicine. Current Opinion in Endocrinology & Diabetes and Obesity, 19, 183-189. https://doi.org/10.1097/MED.0b013e328353732f

  3. 3. Simó, R., Barbosa-Desongles, A., Lecube, A., et al. (2012) Potential Role of Tumor Necrosis Factor-α in Downregulating Sex Hormone-Binding Globulin. Diabetes, 61, 372-382. https://doi.org/10.2337/db11-0727

  4. 4. Zhu, J.-L., Chen, Z., Feng, W.-J., et al. (2019) Sex Hormone-Binding Globulin and Polycystic Ovary Syndrome. Clinica Chimica Acta, 499, 142-148. https://doi.org/10.1016/j.cca.2019.09.010

  5. 5. Goldman, A.L., Bhasin, S., Wu, F.C.W., et al. (2017) A Reappraisal of Testosterone’s Binding in Circulation: Physiological and Clinical Implications. Endocrine Reviews, 38, 302-324. https://doi.org/10.1210/er.2017-00025

  6. 6. Saez-Lopez, C., Brianso-Llort, L., Torres-Torronteras, J., et al. (2017) Resveratrol Increases Hepatic SHBG Expression through Human Constitutive Androstane Receptor: A New Contribu-tion to the French Paradox. Scientific Reports, 7, Article No. 12284. https://doi.org/10.1038/s41598-017-12509-x

  7. 7. Li, L., Feng, Q., Ye, M., He, Y., Yao, A. and Shi, K. (2017) Metabolic Effect of Obesity on Polycystic Ovary Syndrome in Adolescents: A Meta-Analysis. Journal of Obstetrics and Gynaecology, 37, 1036-1047. https://doi.org/10.1080/01443615.2017.1318840

  8. 8. Hammond, G.L. (2011) Diverse Roles for Sex Hor-mone-Binding Globulin in Reproduction. Biology of Reproduction, 85, 431-441. https://doi.org/10.1095/biolreprod.111.092593

  9. 9. Simó, R., Sáez-López, C., Barbosa-Desongles, A., et al. (2015) Novel Insights in SHBG Regulation and Clinical Implications. Trends in Endocrinology & Metabolism, 26, 376-383. https://doi.org/10.1016/j.tem.2015.05.001

  10. 10. Handelsman, D.J., Sikaris, K. and Ly, L.P. (2016) Estimating Age-Specific Trends in Circulating Testosterone and Sex Hormone-Binding Globulin in Males and Females across the Lifespan. Annals of Clinical Biochemistry, 53, 377-384. https://doi.org/10.1177/0004563215610589

  11. 11. Li, M.-F., Zhou, X.-M. and Li, X.-L. (2018) The Effect of Ber-berine on Polycystic Ovary Syndrome Patients with Insulin Resistance (PCOS-IR): A Meta-Analysis and Systematic Review. Evidence-Based Complementary and Alternative Medicine, 2018, Article ID: 2532935. https://doi.org/10.1155/2018/2532935

  12. 12. Petersen, M.C. and Shulman, G.I. (2018) Mechanisms of Insulin Ac-tion and Insulin Resistance. Physiological Reviews, 98, 2133-2223. https://doi.org/10.1152/physrev.00063.2017

  13. 13. Tawfeek, M.A., Alfadhli, E.M., Alayoubi A.M., et al. (2017) Sex Hormone Binding Globulin as a Valuable Biochemical Marker in Predicting Gestational Diabetes Mellitus. BMC Wom-en’s Health, 17, Article No. 18. https://doi.org/10.1186/s12905-017-0373-3

  14. 14. Dapas, M., Lin, F.T.J., Nadkarni, G.N., et al. (2020) Distinct Subtypes of Polycystic Ovary Syndrome with Novel Genetic Associations: An Unsupervised, Phenotypic Clustering Analysis. PLOS Medicine, 17, e1003132. https://doi.org/10.1371/journal.pmed.1003132

  15. 15. Lin, X.F., Wu, R.R., Du, J., et al. (2015) Exploring the Signif-icance of Sex Hormone-Binding Globulin Examination in the Treament of Women with Polycystic Ovarian Syndrome (PCOS). Clinical and Experimental Obstetrics & Gynecology, 42, 315-320. https://doi.org/10.12891/ceog1779.2015

  16. 16. Saez-Lopez, C., Villena, J.A., Simó, R., et al. (2020) Sex Hor-mone-Binding Globulin Overexpression Protects against High-Fat Diet-Induced Obesity in Transgenic Male Mice. The Journal of Nutritional Biochemistry, 85, Article ID: 108480. https://doi.org/10.1016/j.jnutbio.2020.108480

  17. 17. Sáez-López, C., Salcedo-Allende, M.T., Hernandez, C., et al. (2019) Sex Hormone-Binding Globulin Expression Correlates with Acetyl-Coenzyme a Carboxylase and Triglyceride Content in Human Liver. The Journal of Clinical Endocrinology & Metabolism, 104, 1500-1507. https://doi.org/10.1210/jc.2018-00740

  18. 18. Feng, C., Jin, Z., Chi, X., et al. (2018) SHBG Expression Is Correlated with PI3K/AKT Pathway Activity in a Cellular model of Human Insulin Resistance. Gynecological Endocrinology, 34, 567-573. https://doi.org/10.1080/09513590.2017.1411474

  19. 19. Chang, R.J. (2007) The Reproductive Phenotype in Polycys-tic Ovary Syndrome. Nature Clinical Practice Endocrinology & Metabolism, 3, 688-695. https://doi.org/10.1038/ncpendmet0637

  20. 20. Cho, L.W., Jayagopal, V., Kilpatrick, E.S., et al. (2006) The LH/FSH Ratio Has Little Use in Diagnosing Polycystic Ovarian Syndrome. Annals of Clinical Biochemistry, 43, 217-219. https://doi.org/10.1258/000456306776865188

  21. 21. Huang, M., Liu, J.J., Lin, X.C., et al. (2018) Relationship be-tween Dietary Carbohydrates Intake and Circulating Sex Hormone-Binding Globulin Levels in Postmenopausal Women. Journal of Diabetes, 10, 467-477. https://doi.org/10.1111/1753-0407.12550

  22. 22. Ong, M., Cheng, J., Jin, X., et al. (2019) Paeoniflorin Extract Re-verses Dexamethasone-Induced Testosterone Over-Secretion through Downregulation of Cytochrome P450 17A1 Ex-pression in Primary Murine Theca Cells. Journal of Ethnopharmacology, 229, 97-103. https://doi.org/10.1016/j.jep.2018.09.006

  23. 23. Cinar, N. and Gurlek, A. (2013) Association between Novel Adi-pocytokines Adiponectin, Vaspin, Visfatin, and Thyroid: An Experimental and Clinical Update. Endocrine Connections Journal, 2, R30-R38. https://doi.org/10.1530/EC-13-0061

  24. 24. Simó, R., Saez-Lopez, C., Lecube, A., et al. (2014) Adiponectin Upregu-lates SHBG Production: Molecular Mechanisms and Potential Implications. Endocrinology, 155, 2820-2830. https://doi.org/10.1210/en.2014-1072

  25. 25. Liu, C.-C., Huang, S.-P., Cheng, K.-H., et al. (2017) Lower SHBG Level Is Associated with Higher Leptin and Lower Adiponectin Levels as well as Metabolic Syndrome, Independent of Testosterone. Scientific Reports, 7, Article No. 2727. https://doi.org/10.1038/s41598-017-03078-0

  26. 26. Simó, R., Barbosa-Desongles, A., Sáez-Lopez, C., et al. (2012) Molecular Mechanism of TNFα-Induced Down-Regulation of SHBG Expression. Molecular Endocrinology, 26, 438-446. https://doi.org/10.1210/me.2011-1321

  27. 27. Oróstica, L., Astorga, I., Plaza-Parrochia, F., et al. (2016) Proinflammatory Environment and Role of TNF-α in Endometrial Function of Obese Women Having Polycystic Ovarian Syndrome. International Journal of Obesity, 40, 1715-1722. https://doi.org/10.1038/ijo.2016.154

  28. 28. Yamazaki, H., Kushiyama, A., Sakoda, H., et al. (2018) In Vitro Protec-tive Effect of Sex Hormone-Binding Globulin against Metabolic Syndrome: Evidence Showing Anti-Inflammatory and Lipolytic Effects on Adipocytes and Macrophages. Mediators of Inflammation, 2018, Article ID: 3062319. https://doi.org/10.1155/2018/3062319

  29. 29. 张杰, 李丽娟, 刘亚楠. 当归芍药散加味联合达英-35治疗多囊卵巢综合征临床研究[J]. 新中医, 2023, 55(4): 7-12.

  30. 30. 辛秀丽, 袁少飞, 关敬之. 补肾调经汤联合来曲唑治疗肾虚肝郁型多囊卵巢综合征所致不孕症临床观察[J]. 中国中医药现代远程教育, 2019, 17(12): 101-103.

  31. 31. 闫嘉营, 刘利红, 谢德芳, 吴翔玉, 伍东月. 补肾调经育子汤联合来曲唑对肾虚血瘀型多囊卵巢综合征不孕患者卵泡发育及血清性激素结合球蛋白水平的影响[J]. 中国性科学, 2021, 30(3): 101-104.

  32. 32. 何丹娟, 梁少荣, 黄晓桃. 穴位埋线治疗肥胖型多囊卵巢综合征的临床研究[J]. 湖北中医杂志, 2020, 42(2): 12-16.

  33. 33. 王铭, 崔振军. 加味补肾活血调经汤联合桂枝茯苓胶囊对多囊卵巢综合征不孕患者血清SHBG、Visfatin水平变化及预后妊娠率的影响[J]. 中国妇幼保健, 2019, 34(4): 883-886.

  34. 34. 张晓丹, 蔡云, 许昕. 益肾祛浊方对PCOS-IR大鼠Ghrelin、SHBG及VF的影响[J]. 中国医药导报, 2017, 14(33): 9-12+21

  35. 35. 王炼炼, 李聪, 杨曦, 孟江萍, 幸贵邦. Ghrelin基因在多囊卵巢综合征患者卵巢颗粒细胞中的表达[J]. 重庆医科大学学报, 2015, 40(2): 239-242.

  36. 36. 李颖, 翁锡全, 林文弢. 高脂饮食诱导胰岛素抵抗模型大鼠血清内脂素变化[J]. 中国组织工程研究与临床康复, 2008, 12(24): 4693-4696.

  37. 37. 孙玉英, 李淑萍, 谈勇. 滋阴补阳方序贯法与西药联合治疗多囊卵巢综合征高雄激素血症临床研究[J]. 新中医, 2020, 52(3): 100-103.

  38. NOTES

    *通讯作者。

期刊菜单